1. Pink Sheet
  2. >>Legislation

US FDA Would Get Funding Boost Under House Coronavirus Stimulus Bill

 
• By Derrick Gingery

Agency appears to have a fair bit of flexibility in how to spend the additional $80m slated for coronavirus activities.

Capitol House
The additional coronavirus funds could be used for pre- and post-market product work, emergency use authorizations and other activities. • Source: Shutterstock

US Food and Drug Administration coronavirus activities would see another substantial jump in support as part of legislation proposed in the House of Representatives.

An additional $160m is allocated to the agency in the Take Responsibility for Workers and Families Act, a third coronavirus-related stimulus bill aimed at fighting the pandemic and helping the wobbling economy

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Pink Sheet

EU Shaping Biotech Act To Unleash SME Potential

 
• By Neena Brizmohun

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.

New EU Filings

 
• By Neena Brizmohun

Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.